81 results about "Cytidylic Acids" patented technology

The invention discloses a new method for synthesizing uridylic acid disodium. The method comprises the following steps: adding cytidylic acid and sodium nitrite in deionized water, and dropwise adding inorganic or organic acid at the constant temperature of minus 5 DEG C-0 DEG C; stirring the solution and heating to 10-60 DGE C, reacting for 1-12 hours, and introducing steam for steam distillation after the reaction is finished so as to obtain a uridylic acid solution; regulating the pH of the uridylic acid solution to 7.0-8.5 with alkali, distilling at reduced pressure until a liquid is not distilled out; adding 95% ethanol the weight of which is 3-12 times that of cytidylic acid, heating and refluxing for 0.5-6 hours under the condition of stirring, crystallizing, and filtering so as to obtain crude uridylic acid disodium; and dissolving crude uridylic acid disodium in a proper amount of water, recrystallizing with ethanol the weight of which is 1-3.5 times that of the crude uridylic acid disodium, filtering and drying so as to obtain the uridylic acid disodium product. By using the method, the yield of uridylic acid disodium is above 92.75%, the purity of uridylic acid disodium by detection of high performance liquid chromatography (HPLC) is more than 99.50%, and the purity of uridylic acid disodium by detection of ultraviolet (UV) light is above 98.50%. The method has the advantages of simple and reasonable process, good product quality stability, low production cost and the like, and is easy to be applied to massively production.

The invention discloses a method for preparing citicoline sodium by utilizing oxalyl chloride. The method is characterized by comprising the following steps of: by taking choline chloride calcium phosphate (P-choline) as a raw material, dissolving in organic amine not containing reactive hydrogen, adding oxalyl chloride for reacting for 0.5-2 hours after adding benzene for removing water in an azeotropic manner, and then, adding cytidylic acid (5'-CMP) for reacting.

The invention relates to a method for preparing 5'-cytidylic acid from a composite solvent and a bind acid agent. The method comprises the following detailed steps of: (1) preparing the composite solvent which contains a sulfoxide solvent and alkyl three-low level phosphate; (2) adding a phosphorylation agent, namely at the temperature of -2 to 2 DEG C, dropwise adding the phosphorylation agent into the composite solvent to perform an intervention reaction, wherein the phosphorylation agent and a certain amount of water in the composite solvent react to generate a part of hydrate; (3) adding cytidine, namely gradually adding the cytidine at the temperature of 0 to 5 DEG C to perform reaction for 3 to 5 hours; and (4) adding the bind acid agent, namely adding the phosphorylation agent and the bind acid agent in a proportion of 100:0.8-100:0.6. The yield of the product obtained by the method is over 90 percent; the ultraviolet content of the generated 5'-cytidylic acid is over 98 percent; and the high-performance liquid chromatography (HPLC) content of the generated 5'-cytidylic acid is over 98 percent.

The invention relates to a pharmaceutical composition of dsRNA and astragalus polysaccharide and application thereof, in particular to the pharmaceutical composition applied to viral infection prevention and treatment of cultured animals. The pharmaceutical composition is formed by combining the astragalus polysaccharide and the dsRNA according to a certain proportion, wherein the astragalus polysaccharide has the content range of 20-50mg / ml; the dsRNA (polyinosinic acid) has the content range of 1-5mg / ml and the molecular weight range of 200-500bp; and the main components of the astragalus polysaccharide and the dsRNA are processed by matching liquid, filtering, filling and encapsulating as well as sterilizing according to water injection production technology, and the pharmaceutical composition can be obtained after being checked to be qualified. A certain amount of polyinosinic cytidylic acid is added into water for injection and dissolved under the condition of 20-60 DEG C; then, equimolar polycytidylic acid is added into the solution to be dissolved; heat preservation and pairing are carried out for 15-50min; and right amount of astragalus polysaccharide is added, evenly mixed and treated by filtering, filling and encapsulating as well as sterilizing. Therefore, the invention is applicable to improving the immunity of livestock, poultry and aquatic animals, and improves the prevention and treatment for virus diseases.

The invention relates to the field of immunology, and particularly discloses a mucosal immunity preparation capable of resisting infection and tumors. The effective component of the preparation is a mucosal immunity substance which is formed by combining polyinosinic acid-polycytidylic acid, a non-antibiotic amino compound, metal positive ions, and PEG and / or PEI and / or PLGA and / or positive ion polymers through hydrogen bonds and other chemical bonds. The preparation is a spray or an aerosol in dosage form, but preferentially, the preparation does not contain ingredients utilized by common sprays or ingredients utilized by aerosols, and propellants. The mucosal immunity preparation can achieve the slow-release function partially or wholly, the half-life period of the mucosal immunity preparation is prolonged, the availability and effectiveness of drugs are improved, and the compliance of a patient is improved. The mucosal immunity preparation can promote mucosal immunity of the human body by means of the mucosal immunity, and then promote activation and proliferation, including whole-body nonspecific immunity, humoral immunity and cellular immunity, of all immune cells instead of only acting on the local part of a disease wound, and thus the preventing and treating effects of resisting infection and tumors are achieved.

The present invention relates to compositions comprising particles, each of said particles comprising a complex of at least one double-stranded polyribonucleotide, such as polyinosinic-polycytidylic acid [poly(I:C)], and at least one linear polyalkyleneimine. The particles are also characterized by their monomodal diameter distribution and z-average diameter within specific ranges. The present invention additionally relates to use of said compositions as medicaments, in particular for the treatment of a cell growth disorder characterized by abnormal growth of human or animal cells, as well as to processes for the preparation of said compositions.

The invention discloses a feed for treating a fatty liver disease of turtles and a preparation method thereof, and belongs to the technical field of turtle feed processing. The feed is prepared from, by weight, 30-50 parts of silkworm pupa meal, 50-70 parts of manihot utilissima powder, 8-16 parts of table salt, 6-14 parts of dimethyl-beta-propiothetin, 5-9 parts of betaine, 4-8 parts of glycine, 4-8 parts of cytidylic acid, 0.2-0.6 part of Tomatin polypeptide, 1-3 parts of citronellal and 15-42 parts of traditional Chinese medicine preparation. The feed is prepared through the steps of drying, smashing, screening, liquid medicine extracting, concentrating, mixing, pelletizing, sterilizing and the like. According to the feed for treating the fatty liver disease of the turtles, the effects of multiple traditional Chinese medicines are synthesized, the effects of resisting bacteria, diminishing inflammation, enhancing the body immune function and the like can be achieved, the cure rate of the fatty liver disease of the turtles can be effectively increased, and the death rate of the fatty liver disease of the turtles can be effectively decreased; the feed is reasonable in preparation, rich in nutrition and capable of increasing the feed intake of the turtles suffering from the fatty liver disease and increasing the growth speed.

The purpose of the present invention is to provide a riemerella anatipestifer bacterial ghost vaccine loaded with polyinosinic acid-polycytidylic acid having interferon inducing activity and added with chitosan oligosaccharide as an adjuvant. According to the technical scheme, a temperature control expression vector is constructed and is electrotransformed into riemerella anatipestifer protoplast, positive clones are screened and then are subjected to bacterial amplification culture at a temperature of 28 DEG C, lysis gene expression is induced at a temperature of 42 DEG C, polylysine is added to continuously act when the OD600 is no longer be reduced so as to completely lyze the live bacteria, centrifugation is performed to separate the bacteria, the dried bacteria and a 6 mg / mL Poly I:C solution according to an equal ratio so as to make the Poly I:C be embedded into the bacterial ghosts, a 2% chitosan oligosaccharide aqueous solution is added, stirring is performed to form a uniform mixture, sub-packaging is performed into penicillin bottles, and freeze-drying is performed so as to obtain the novel riemerella anatipestifer bacterial ghost vaccine. According to the present invention, the prepared riemerella anatipestifer bacterial ghost vaccine is immunized through drinking water, such that the local immunity on the respiratory tract mucous membrane and the digestive tract mucous membrane can be irritated, the humoral immunity can be stimulated, and the protection effect on the human body is not different from the injection immunity.

The present invention relates to compositions comprising particles, each of said particles comprising a complex of at least one double-stranded polyribonucleotide, such as polyinosinic-polycytidylic acid [poly(I:C)], and at least one linear polyalkyleneimine. The particles are also characterized by their monomodal diameter distribution and z-average diameter within specific ranges. The present invention additionally relates to use of said compositions as medicaments, in particular for the treatment of a cell growth disorder characterized by abnormal growth of human or animal cells, as well as to processes for the preparation of said compositions.